Plain-English translation of NCT05585814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , combined with and chemotherapy (a drug called CapeOX), can help shrink rectal cancer before surgery. The study involves 30 patients and focuses on a specific type of rectal cancer. Researchers want to see if this combination therapy is both effective and safe when given before surgery.
Advanced rectal cancer is difficult to treat, and surgery alone may not be enough to stop the cancer from returning. This trial is exploring whether giving this three-drug combination before surgery might improve outcomes by shrinking the tumor and helping the body's immune system fight the cancer.
You would receive four cycles of treatment over about 12 weeks before surgery, with each cycle lasting 3 weeks. During each cycle, you would take a chemotherapy pill by mouth twice daily for 2 weeks, receive two intravenous infusions (one of and one of ) on Day 1, and have blood tests and scans to monitor your progress. After completing the four cycles, you would receive one more shorter cycle of chemotherapy before proceeding to surgery.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Changzheng Hospital
Enrollment target
~30 participants
Started
May 2023
Primary completion
September 2024
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2026.